Loading
A phase 1/2 trial of SHR-A2102, Adebrelimab, Cetuximab in head and neck squamous cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer is a phase 1/2 interventional study registered as NCT07059221 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 210 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-03. Interventions recorded: SHR-A2102, Adebrelimab, Cetuximab, SHR-9839(sc), Carboplatin / Cisplatin. Conditions listed: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/